-transparent.png){kind=logo}
In many controlled studies, CVD103-HgR has been shown to be safe and immunogenic and to offer a significant degree of protection against experimental cholera after a single dose. Its minimal excretion and limited ability to compete and survive in various ecosystems indicate that this strain presents little risk to the environment. Furthermore, the potential of CVD103-HgR to regain virulence by acquisition of the CT A or LT A gene is extremely remote even under optimal conditions. Therefore, CVD103-HgR possesses those traits desired in a live oral attenuated vaccine produced by recombinant DNA technology.
Related Publications
S J Cryz, and
J Kaper, and
C Tacket, and
J Nataro, and
M M Levine
April 1995,
Lancet (London, England),
S J Cryz, and
J Kaper, and
C Tacket, and
J Nataro, and
M M Levine
April 1996,
Vaccine,
S J Cryz, and
J Kaper, and
C Tacket, and
J Nataro, and
M M Levine
April 1995,
Infection and immunity,
S J Cryz, and
J Kaper, and
C Tacket, and
J Nataro, and
M M Levine
February 1999,
The Journal of infectious diseases,
S J Cryz, and
J Kaper, and
C Tacket, and
J Nataro, and
M M Levine
June 2004,
Vaccine,
S J Cryz, and
J Kaper, and
C Tacket, and
J Nataro, and
M M Levine
May 1990,
Infection and immunity,
S J Cryz, and
J Kaper, and
C Tacket, and
J Nataro, and
M M Levine
July 2000,
Vaccine,
S J Cryz, and
J Kaper, and
C Tacket, and
J Nataro, and
M M Levine
October 1993,
Infection and immunity,
S J Cryz, and
J Kaper, and
C Tacket, and
J Nataro, and
M M Levine
January 1994,
The Journal of infectious diseases,
S J Cryz, and
J Kaper, and
C Tacket, and
J Nataro, and
M M Levine
October 1995,
The Journal of infectious diseases,
